Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

BridgeBio Pharma, Inc. BBIO

Healthcare  —  Biotechnology
65.57 (0.71) (1.07%) as of 25 Sep
Market cap
$13.1B
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

BridgeBio Pharma, Inc. (BBIO) Business Profile

Updated before January 2025

Company Overview

BridgeBio Pharma, Inc. (BBIO) is a biotechnology company founded in 2015 by Neil Kumar, Ph.D., Andrew Lo, Ph.D., and Charles Homcy, M.D. The company is headquartered in Palo Alto, California, and is dedicated to discovering, developing, and delivering transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. BridgeBio operates with a mission to address unmet medical needs by focusing on genetic conditions that have been historically underserved by the pharmaceutical industry.

The company is led by a team of seasoned professionals with extensive experience in the biotechnology and pharmaceutical sectors. Neil Kumar, Ph.D., serves as the CEO and has been instrumental in shaping the company’s strategic direction. Other key members of the leadership team include Brian Stephenson, Ph.D., CFA, who serves as Chief Financial Officer, and Eli Wallace, Ph.D., the Chief Scientific Officer. Together, the leadership team drives BridgeBio’s mission to bring innovative therapies to market.

Core Business Segments

BridgeBio Pharma operates across several core business segments, primarily focusing on genetic diseases and oncology. The company’s portfolio includes a range of investigational therapies and approved products aimed at addressing rare and underserved conditions.

Genetic Diseases

BridgeBio’s genetic disease segment focuses on developing therapies for rare genetic disorders. Key programs include:

  • Encaleret: A treatment for autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic condition that affects calcium regulation.
  • BBP-418: A therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), a progressive muscle-wasting disease.
  • BBP-631: A gene therapy for congenital adrenal hyperplasia (CAH), a genetic disorder affecting adrenal gland function.

Oncology

In the oncology segment, BridgeBio is developing targeted therapies for cancers with clear genetic drivers. Key programs include:

  • BBP-398: A SHP2 inhibitor for solid tumors with specific genetic mutations.
  • BBP-454: A KRAS inhibitor targeting cancers driven by KRAS mutations.
  • BBP-418: A therapy for genetically defined cancers, leveraging the company’s expertise in precision medicine.

Other Therapeutic Areas

BridgeBio also explores opportunities in other therapeutic areas, including dermatology and cardiology, where genetic factors play a significant role. The company’s diversified pipeline reflects its commitment to addressing a broad spectrum of genetic conditions.

Business Model

BridgeBio’s business model is centered on identifying and developing therapies for genetic diseases and cancers with clear genetic drivers. The company employs a unique approach that integrates drug discovery, development, and commercialization under one roof. This model allows BridgeBio to streamline the drug development process and bring therapies to market more efficiently.

Revenue generation primarily comes from licensing agreements, collaborations, and the commercialization of approved therapies. The company also partners with academic institutions, research organizations, and other biotech firms to leverage cutting-edge science and accelerate the development of its pipeline.

Strategic Direction

BridgeBio’s strategic direction is focused on expanding its pipeline, advancing clinical programs, and achieving regulatory approvals for its investigational therapies. Key priorities include:

  • Pipeline Expansion: The company aims to broaden its portfolio by identifying new genetic targets and developing innovative therapies.
  • Regulatory Approvals: BridgeBio is committed to securing approvals for its late-stage programs, including Encaleret and BBP-418.
  • Global Reach: The company plans to expand its presence in international markets to ensure patients worldwide have access to its therapies.
  • Sustainability Goals: While not explicitly stated, BridgeBio’s focus on genetic diseases aligns with broader sustainability objectives by addressing unmet medical needs and improving patient outcomes.

Competitive Landscape

BridgeBio operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Vertex Pharmaceuticals: Known for its focus on genetic diseases, particularly cystic fibrosis.
  • BioMarin Pharmaceutical: A leader in rare genetic disorders.
  • Sarepta Therapeutics: Specializes in genetic therapies for neuromuscular diseases.
  • Blueprint Medicines: Focuses on precision therapies for genetically defined cancers.

Despite the competition, BridgeBio differentiates itself through its integrated business model, focus on genetic conditions, and robust pipeline.

Risk Factors

BridgeBio faces several risks that could impact its operations and financial performance:

  • Regulatory Risks: The company’s success depends on obtaining regulatory approvals for its investigational therapies.
  • Market Dependence: Revenue generation is heavily reliant on the success of its pipeline programs.
  • Supply Chain Disruptions: Any disruptions in the supply chain could delay clinical trials and commercialization efforts.
  • Competition: Intense competition in the biotechnology sector could impact market share and pricing.
  • Financial Risks: As a clinical-stage company, BridgeBio may face challenges in securing funding for its operations and pipeline development.

Recent Developments

BridgeBio has made significant progress in advancing its pipeline and achieving key milestones. Recent developments include:

  • Clinical Trial Updates: Positive data from clinical trials of Encaleret and BBP-418, demonstrating their potential to address unmet medical needs.
  • Partnerships: New collaborations with academic institutions and biotech firms to accelerate drug discovery and development.
  • Regulatory Submissions: Progress in submitting regulatory applications for late-stage programs.
  • Global Developments: The company continues to navigate challenges posed by the COVID-19 pandemic, ensuring the continuity of its clinical programs.

Investment Considerations

Investors considering BridgeBio Pharma should weigh the following strengths and risks:

Strengths

  • Robust Pipeline: A diverse portfolio of investigational therapies targeting genetic diseases and cancers.
  • Experienced Leadership: A seasoned management team with a proven track record in biotechnology.
  • Innovative Business Model: An integrated approach to drug discovery, development, and commercialization.

Risks

  • Regulatory Uncertainty: Dependence on regulatory approvals for revenue generation.
  • Financial Challenges: High R&D expenses and reliance on external funding.
  • Market Competition: Intense competition from established and emerging players.

Conclusion

BridgeBio Pharma, Inc. is a pioneering biotechnology company with a strong focus on genetic diseases and precision oncology. With a robust pipeline, innovative business model, and experienced leadership, the company is well-positioned to address unmet medical needs and drive future growth. However, investors should carefully consider the risks associated with regulatory approvals, financial sustainability, and market competition. As BridgeBio continues to advance its pipeline and expand its global reach, it remains a compelling player in the biotechnology sector.